ICER’s Protocol on Unsupported Price Increases Discusses 250 Drugs
The Institute for Clinical and Economic Review (ICER) recently published a protocol detailing how it determines unjustified price increases. The [...]
Upcoming Virtual Discussion on Reducing High Prescription Drug Prices Without Impacting Innovation
Patients for Affordable Drugs will host a virtual session on overcoming high drug prices on May 18th at 7 PM [...]
New Report Offers Global Market Insight and Highlights Critical HEOR RWD Trends
A new report discusses health economics and outcomes research (HEOR) trends expected to impact the global economy for the next [...]
New Study Analyzes List and Net Prices of Diabetes Drugs
A new study considers the prices of three categories of drugs used in diabetes. The authors note an increase in [...]
Xcenda Leader Provides Insight on Biosimilars for Payers and Pharma
Managing Director Allen Lising of Xcenda’s FormularyDecisions shared his thoughts on biosimilars. He notes that when it comes to the [...]
New JMCP Article Discusses Calculating the Price Tag of Gene Therapies
An article published in the Journal of Managed Care & Specialty Pharmacy (JMCP) focuses on the price considerations of new [...]
Insights on Excessive Drug Costs and Using QALYs to Determine Value
Dan Ollendorf of the Center for the Evaluation of Value and Risk in Health at Tufts University Medical Center and [...]
How Can RWD Improve Our Global Response to the Next Pandemic?
Panalgo CEO and Founder Joseph Menzin and Center for the Evaluation of Value and Risk in Health Director Peter Neumann [...]
ICER’s New Whitepaper Features Insight on FDA’s Accelerated Approval Pathway and Proposes Drug Pricing Reform
The Institute for Clinical and Economic Review (ICER) published a whitepaper discussing the Food and Drug Administration’s Accelerated Approval Pathway (AAP). The [...]
Does Hydroxychloroquine Work? New COVID-19 Evidence Accelerator Report Uses RWD to Determine Patient Outcomes
The COVID-19 Evidence Accelerator has published a new report in PLOS One. The manuscript examines how hydroxychloroquine and azithromycin affect [...]
How Will Europe Use RWE in Regulatory Decisions and HTAs?
Aetion’s Senior Director of European Business Development Pierre Engel discusses trends in Europe’s use of real world evidence (RWE). He [...]
Aetion President and Co-Founder Discusses RWE in Recent Coronavirus Study
Aetion Co-Founder and President Jeremy Rassen discusses the use of real world evidence (RWE) in a recent Science paper. Researchers [...]
New Study Examines Cost-Effectiveness, Equity, Caregiver Burden, and Other Value Elements in 20 ICER Reports
A new article, published in the Journal of Managed Care and Specialty Pharmacy, examines 32 value elements, including health equity [...]
NICE’s Five-Year Plan Features RWE and RWD
Aetion’s Scientific Partnerships Lead Ashley Jaksa discusses the four new strategies released by the UK’s National Institute for Health and [...]
Aetion Analyst Discusses Using RWE in Rare Disease Clinical Trials
Senior Scientific Analyst Adina Estrin at Aetion discusses how RWE (real world evidence) can be used in constructing external control [...]
New Report Discusses RWD and RWE in Regulatory Approval Process, Notes 82% of Submissions Using RWE Gain Orphan Drug Designation
A report published in Clinical Pharmacology & Therapeutics discusses the use of RWD (real world data) and RWE (real world [...]
Amazon Care Pilot Program Expands Nationwide
Amazon’s venture into healthcare is expanding as Amazon Care becomes available throughout the country. The pilot healthcare program could jeopardize [...]
New Whitepaper Features Insight on Virtual Stakeholder Engagement
A new whitepaper discusses how life sciences companies can optimize their stakeholder engagement strategies. Although virtual engagement was taking place [...]
Can Companies Order COVID-19 Vaccination? Legal Challenges Have Begun
The US is rapidly vaccinating its population with vaccines that received the Emergency Use Authorization (EUA) by the Food and [...]
COVID-19 Leaves Companies Wondering How to Navigate the Future
The impact of COVID-19 cannot be understated. Kantar’s Chief Procurement Officer (CPO) Stephen Day discusses his thoughts on industry trends [...]
Cytel Research Specialist Discusses Benefits of Bayesian Network Models for Clinicians and Clinical Trials
A recent Cytel paper, published in JCO Clinical Cancer Informatics, uses a Bayesian Network Model to accurately predict outcomes in cancer [...]
HealthVerity Clinical Trial Optimization Approach Considers RWD Advantages and Promotes Equity
RWD (real world data) is changing the way clinical trials are designed and conducted. HealthVerity discusses important consideration for using [...]
Major Payers Face Criticism Regarding Specialty Pharmacy Policies
Several large insurance companies, including BlueCross BlueShield of Tennessee, Anthem, Cigna, Aetna, and UnitedHealthcare, are facing criticism due to variations [...]
New Podcast Featuring ICER President on Consequences of High Drug Prices and Thoughts on New Cholesterol-Reducing Drugs
A recent Managed Healthcare Executive podcast featured ICER President and Founder Dr. Steven Pearson. ICER recently published a report on [...]
Cytel Blog on Using Bayesian Methods to Improve Clinical Trials
A Cytel blog post discusses how using Bayesian methods can lead to several key benefits in clinical trial design, including [...]